Federated Hermes Inc. Sells 267,146 Shares of ADMA Biologics Inc $ADMA

Federated Hermes Inc. trimmed its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 22.2% during the second quarter, HoldingsChannel reports. The fund owned 936,981 shares of the biotechnology company’s stock after selling 267,146 shares during the period. Federated Hermes Inc.’s holdings in ADMA Biologics were worth $17,062,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ADMA. SVB Wealth LLC bought a new position in ADMA Biologics during the 1st quarter worth about $35,000. Cullen Frost Bankers Inc. boosted its position in shares of ADMA Biologics by 112.5% during the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,081 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of ADMA Biologics by 161.4% during the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company’s stock worth $49,000 after buying an additional 1,493 shares in the last quarter. Ameritas Advisory Services LLC acquired a new stake in ADMA Biologics in the 2nd quarter valued at approximately $46,000. Finally, Toth Financial Advisory Corp lifted its stake in ADMA Biologics by 1,081.6% in the 2nd quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 2,293 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $19.98 on Thursday. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67. The company has a market cap of $4.76 billion, a P/E ratio of 23.23 and a beta of 0.43. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.65 and a current ratio of 7.13. The stock’s 50-day simple moving average is $16.25 and its 200 day simple moving average is $17.27.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. The firm had revenue of $134.22 million during the quarter, compared to the consensus estimate of $131.20 million. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The business’s revenue was up 12.0% compared to the same quarter last year. During the same period last year, the company earned $0.15 earnings per share. As a group, sell-side analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, ADMA Biologics has an average rating of “Buy” and a consensus price target of $28.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.